会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 25. 发明授权
    • Therapeutic agent for malignant tumors expressing MHC class II
    • 表达MHC II类恶性肿瘤的治疗剂
    • US09303083B2
    • 2016-04-05
    • US13877844
    • 2011-10-04
    • Shuji MatsuokaYasuyuki Ishii
    • Shuji MatsuokaYasuyuki Ishii
    • C07K16/28C07K16/18C07K16/30
    • C07K16/18C07K16/2803C07K16/30C07K2317/34G01N2333/70539
    • Provided is a novel therapeutic agent specific for a malignant tumor expressing MHC class II. The present invention provides an antibody recognizing a protein constituting MHC class II expressed on a malignant tumor, the antibody comprising at least one selected from heavy chain CDR1 (amino acid sequence represented by positions 49 to 54 of SEQ ID NO: 54), heavy chain CDR2 (amino acid sequence represented by positions 69 to 84 of SEQ ID NO: 54), heavy chain CDR3 (amino acid sequence represented by positions 117 to 128 of SEQ ID NO: 54), light chain CDR1 (amino acid sequence represented by positions 46 to 55 of SEQ ID NO: 56), light chain CDR2 (amino acid sequence represented by positions 71 to 77 of SEQ ID NO: 56), and light chain CDR3 (amino acid sequence represented by positions 100 to 108 of SEQ ID NO: 56).
    • 提供一种特异于表达II类MHC的恶性肿瘤的新型治疗剂。 本发明提供一种抗体,其识别构成在恶性肿瘤上表达的II类MHC的蛋白质,所述抗体包含选自重链CDR1(SEQ ID NO:54的49至54位的氨基酸序列)中的至少一种,重链 CDR2(SEQ ID NO:54的第69〜84位的氨基酸序列),重链CDR3(SEQ ID NO:54的117〜128位的氨基酸序列),轻链CDR1(由位置 SEQ ID NO:56的46〜55),轻链CDR2(由SEQ ID NO:56的71〜77位表示的氨基酸序列)和轻链CDR3(SEQ ID NO: :56)。
    • 29. 发明申请
    • METHOD FOR QUANTIFICATION OF ANTIGEN-SPECIFIC CANINE OR HUMAN IGE
    • 抗原特异性犬或人脑的定量方法
    • US20110111529A1
    • 2011-05-12
    • US12992476
    • 2009-05-12
    • Kenichi MasudaYasuyuki IshiiNobutaka Yasuda
    • Kenichi MasudaYasuyuki IshiiNobutaka Yasuda
    • G01N33/566
    • G01N33/6854C07K16/06C07K16/42C07K16/4291C07K2317/33C12N5/163G01N33/536G01N33/537G01N33/543G01N33/96G01N2333/435G01N2469/20G01N2496/05G01N2800/24Y10S435/975Y10T436/10Y10T436/106664
    • Disclosed is a convenient and effective means for quantifying an antigen-specific canine or human IgE. Specifically disclosed is a method for quantifying an antigen-specific canine IgE, which comprises the following steps (A) to (D): (A) contacting a biological sample collected from a subject with an antigen to conjugate IgE contained in the sample with the antigen; (B) measuring the quantity of IgE in a standard sample collected from an experimental animal which is different from the subject and has been sensitized with the same antigen as that used in step (A) by using a substance capable of recognizing both IgE from the subject and IgE from the experimental animal, thereby producing a standard curve; (C) detecting a conjugate formed in step (A) by using the same substance capable of recognizing both IgE from the subject and IgE from the experimental animal as that used in step (B); and (D) determining the quantity of IgE in the biological sample collected from the subject by utilizing the quantity of the conjugate detected in step (C) and the standard curve produced in step (B). Also specifically disclosed is a method for quantifying an antigen-specific human IgE.
    • 公开了用于定量抗原特异性犬或人IgE的方便和有效的方法。 具体公开的是定量抗原特异性犬IgE的方法,其包括以下步骤(A)至(D):(A)使从受试者收集的生物样品与抗原接触,将样品中含有的IgE与 抗原; (B)测量从与受试者不同的实验动物收集的标准样品中的IgE的量,并且已经用与步骤(A)中使用的相同的抗原致敏,通过使用能够识别来自 受试者和IgE,从而产生标准曲线; (C)通过使用能够从受试者中识别出两种IgE的相同物质和步骤(B)中使用的实验动物的IgE,检测步骤(A)中形成的缀合物; 和(D)通过利用在步骤(C)中检测到的共轭物的量和步骤(B)中产生的标准曲线来确定从受试者收集的生物样品中的IgE的量。 还具体公开了一种定量抗原特异性人IgE的方法。